Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of SGLT2 on Glucosuria in HNF1A-MODY
NCT05417646Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of empagliflozin in maturity-onset diabetes of the young type 3 (4 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Urinary glucose excretion at 3 hours. Started Jun 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
maturity-onset diabetes of the young type 3
Beyond the preview
Go deeper on NCT05417646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05417646.